Antibe Therapeutics (ATE) Shares Up 12.5%
Antibe Therapeutics Inc (CVE:ATE)’s share price shot up 12.5% on Thursday . The stock traded as high as C$0.27 and last traded at C$0.27. 295,160 shares changed hands during trading, a decline of 73% from the average session volume of 1,078,938 shares. The stock had previously closed at C$0.24.
The company has a debt-to-equity ratio of 24.97, a quick ratio of 2.60 and a current ratio of 4.26.
In other Antibe Therapeutics news, Director Walter Minnes Macnee bought 150,000 shares of the firm’s stock in a transaction dated Friday, September 28th. The stock was purchased at an average cost of C$0.34 per share, with a total value of C$51,000.00. Also, Director Michael Mcmillan bought 100,000 shares of the firm’s stock in a transaction dated Monday, September 24th. The shares were acquired at an average cost of C$0.31 per share, with a total value of C$31,000.00. Over the last 90 days, insiders have acquired 505,000 shares of company stock worth $152,200.
Antibe Therapeutics Inc, a pharmaceutical development company, originates, develops, and out-licenses patent protected pharmaceuticals in Canada, Europe, and the United States. Its drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs. The company's lead compound is ATB-346, a hydrogen sulfide-releasing derivative of naproxen for treating rheumatoid arthritis, ankylosing spondylitis, and general pain reduction, which has completed Phase IIB gastrointestinal safety study.
Further Reading: Dividend Aristocrat Index
Receive News & Ratings for Antibe Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antibe Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.